Stockbabie NewsFatherMarketNewsMarket Intelligence
MARKETS
Wire · Markets
Markets

Avalo Therapeutics To Present Abdakibart Data At EADV Congress 2026

Sep 23, 2026 · 07:07 AM ET· updated 1h ago

Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker

Share
Why It Matters

Avalo will show new medicine test results at a big doctor conference. This gives people a chance to learn if their treatment might work.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
AVTX16.50
-0.01 (-0.06%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.